Octapharma Corrects Previous Press Release on fibryga® Study
Pharmaceutical company Octapharma has corrected a previously issued press release concerning the use of fibryga® in treating blood loss. The correction clarifies study findings.
Octapharma has corrected a press release originally issued on September 9, 2026, regarding the comparison between its product fibryga® and cryoprecipitate in treating bleeding events. The correction specifically pertains to the second sentence of the fifth paragraph, detailing a secondary analysis of prespecified FIBRES subgroups.
The original release focused on the efficacy and safety of fibryga® compared to cryoprecipitate. The updated information refines the reported outcomes from specific patient subgroups within the FIBRES study, though the nature of the adjustment was not elaborated upon in the initial release.
According to the original release, fewer blood components were transfused when using fibryga® than with cryoprecipitate. The statement suggested a potential for improved performance of fibryga® in certain patient populations.
Octapharma is a global company specializing in the development and manufacturing of plasma protein products. Its portfolio includes treatments for hemophilia and other bleeding disorders, as well as treatments for sepsis and critically ill patients.